v3.26.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses:        
Research and development $ 33,930,000 $ 30,106,000 $ 93,378,000 $ 97,056,000
Research and development related success payments and contingent consideration (63,379,000) 3,124,000 [1] (31,033,000) 15,343,000 [1]
General and administrative 10,943,000 10,285,000 33,183,000 32,110,000
Impairment of long-lived assets 0 0 [1] 0 44,611,000 [1]
Total operating expenses (18,506,000) 43,515,000 [1] 95,528,000 189,120,000 [1]
Income (loss) from operations 18,506,000 (43,515,000) [1] (95,528,000) (189,120,000) [1]
Interest income, net 1,219,000 1,003,000 [1] 3,299,000 2,572,000 [1]
Other income, net 676,000 360,000 [1] 1,785,000 1,207,000 [1]
Net income (loss) $ 20,401,000 $ (42,152,000) [1] $ (90,444,000) $ (185,341,000) [1]
Net income (loss) per common share - basic $ 0.07 $ (0.16) $ (0.31) $ (0.75)
Weighted-average number of common shares - basic 307,002 260,494 293,286 245,580
Net income (loss) per common share - diluted $ 0.07 $ (0.16) $ (0.31) $ (0.75)
Weighted-average number of common shares - diluted 308,790 260,494 293,286 245,580
[1] Certain amounts for the three and nine months ended September 30, 2025 have been reclassified to conform to the presentation as of the three and nine months ended September 30, 2026